Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study
- PDF / 722,900 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 89 Downloads / 148 Views
ORIGINAL ARTICLE
Contrast nephropathy in cancer patients receiving anti‑VEGF therapy: a prospective study Ali Gökyer1 · Ahmet Küçükarda1 · Osman Köstek1 · Muhammet Bekir Hacıoğlu1 · Sernaz Uzunoğlu1 · Osman Kula2 · Nazmi Kurt2 · Sedat Üstündağ3 · Bülent Erdoğan1 · İrfan Çiçin1 Received: 9 March 2020 / Accepted: 13 June 2020 © Japan Society of Clinical Oncology 2020
Abstract Objectives Contrast nephropathy risk has been increasing in cancer patients. Nephrotoxic side effects of anti-vascular endothelial growth factor/receptor (anti-VEGF/R) drugs used in oncologic treatment are also prominent. The purpose of this study was to identify the possible association among anti-VEGF/R drugs use and development of the contrast-induced nephropathy (CIN) in patients with cancers. Methods A total of 92 patients were included in this prospective cross-sectional study. Patients whose glomerular filtration rate (GFR) of
Data Loading...
